

Sylvie Dupont

From: Irene Klatt [IKlatt@clhia.ca]
Sent: Thursday, October 09, 2008 5:13 PM
To: Sylvie Dupont
Subject: RE: REMINDER: PMPRB Notice and Comment on Draft Revised Guidelines -- RAPPEL : Avis et commentaires du CEPMB sur l'ébauche des Lignes directrices révisées

Sylvie,

I'm away from my office at this time until the end of October. The points we made were to recognize the important role PMPRB is engaged in with respect to patented drug prices in Canada. Our industry members support a fair system that is transparent, regardless of the payor involved; one that offers a level playing field and that is not overly burdensome. We recognize that it is important that drugs are both affordable and accessible.

We appreciated the opportunity to serve on the Price Test Working Group and we recognize that these are very complex issues. With respect to the methodologies, we view the dip methodology as having the most transparency in the pricing model. The gap methodology raise concerns for us of unexpected price increases that may be seen as unmanageable for payors.

I am back in late October and if any further documentation or assistance is required, I would be pleased to provide it.

Best regards,

Irene Klatt